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Abstract 
We investigated extramedullary disease in newly diagnosed multiple myeloma patients and 
its impact on outcome following first-line autologous stem cell transplantation. We 
identified 3744 adult myeloma patients who received upfront single (n = 3391) or tandem 
transplantation (n = 353) between 2005 and 2014 with available data on extramedullary 
involvement at diagnosis. The overall incidence of extramedullary disease was 18.2% (n = 
682) and increased per year from 6.5% (2005) to 23.7% (2014). Paraskeletal involvement was 
found in 543 (14.5%) and extramedullary organ involvement in 139 (3.7%). More patients 
with extramedullary organ involvement had multiple involved sites (≥ 2; p < 0.001). In 
patients with single sites compared to patients without the disease, upfront transplantation 
resulted in at least similar 3-year progression-free survival (paraskeletal: p = 0.86, and 
extramedullary organ: p = 0.88). In single paraskeletal involvement, this translated less 
clearly into worse 3-year overall survival (p = 0.07) while single organ involvement was 
significantly worse (p = 0.001). Multiple organ sites were associated with worse outcome (p 
< 0.001 and p = 0.01). First-line treatment with tandem compared with single 
transplantation resulted in similar survival in patients with extramedullary disease at 
diagnosis (p = 0.13, respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Multiple myeloma (MM) accounts for approximately 2% of all new cancer cases and 13% of 
hematological cancers with an age-adjusted incidence of 6 per 100 000 per year in the USA 
and Europe.
1
 Autologous stem cell transplantation (ASCT) and the development of new 
agents have considerably increased the median survival of MM patients.
2
 The disease is 
characterized by a clonal proliferation of malignant plasma cells with a strong dependence 
on the bone marrow (BM) microenvironment.
3
 
However, in some MM patients, myeloma cells escape the BM resulting in extramedullary 
disease (EMD), which can be further characterized by two different types of involvement: 1) 
paraskeletal (PS), consisting of masses that arose from bone lesions and 2) extramedullary 
organ (EM), resulting from hematogenous spread into different organs, skin and lymph 
nodes.
4-5
 At the time of MM diagnosis, the incidence of EM involvement in observational 
studies ranges from 1.7 to 4.5% using a baseline staging that includes whole-body MRI or 
PET-CT.
6
 Paraskeletal involvement is more frequently and varies from 7 to 34.2% due to 
different definitions and access of sensitive imaging techniques.
7-10
 Rates are also considered 
to be higher at relapse or after surgical interventions.
11,12
 Several studies reported that EMD 
was associated with shorter survival rates and thus considered EMD as high-risk feature. 
However, the evidence of the effect of EMD at diagnosis is limited due to small populations, 
heterogenous patient or intervention selection, and relapse settings.
13-16
 Hence, very limited 
data are available to assess the role of EMD at diagnosis of MM patients after upfront ASCT. 
This lack of evidence is striking, since ASCT is standard therapy in first-line therapy in eligible 
patients.
17,18
 
Therefore, the objective of this study was to determine the demographic and clinical 
characteristics of EMD in MM patients at diagnosis and to evaluate its impact on outcome 
after upfront ASCT as first-line therapy. For this purpose, we analyzed 3744 patients with or 
without EMD at diagnosis after upfront single or tandem ASCT who had been reported to the 
European Society for Blood and Marrow Transplantation (EBMT) registry between 2005 and 
2014. 
Methods 
Study design and data collection  
We included adult patients with MM and available data on extramedullary involvement at 
time of diagnosis who received an upfront single ASCT within 12 months from diagnosis or a 
tandem ASCT within six months from first ASCT as first-line therapy and were reported to 
the EBMT registry between January 2005 and December 2014. Patients were considered 
eligible for analysis if there was full data on extramedullary involvement (yes or no) at time 
of diagnosis, its location and number of sites. This study was performed in accordance with 
the principles of the Declaration of Helsinki and approved by the Chronic Malignancies 
Working Party of the EBMT. The EBMT is a non-profit, scientific society representing more 
than 600 transplant centres mainly in Europe. Data are entered, managed, and maintained in 
a central database with internet access. Audits are routinely performed to determine the 
accuracy of the data. Data on extramedullary involvement were extracted from the database 
using Med-B forms. Patients whose transplant data are reported provide informed consent 
to use the information for research purposes in an anonymous way. 
Definitions and statistical analysis 
The primary end point was 3-year progression-free survival (PFS), which was defined as the 
time from ASCT to disease progression or death from any cause. The secondary end points 
were 3-year overall survival (OS), non-relapse mortality (NRM) and response. Overall survival 
was defined as the time from ASCT to death from any cause or last follow-up. Non-relapse 
mortality was defined as death without evidence of relapse or progression, with relapse or 
progression as competing events. Remission, progression and relapse were defined 
according to the standard EBMT criteria.
19
  
Based on the type of extramedullary involvement, we defined three groups of myeloma 
patients: 1) without EMD (MM group), 2) with paraskeletal (PS group) and 3) extramedullary 
organ involvement (EM group). Additionally, we determined and analyzed the impact of the 
number of involved sites as one or multiple (≥ 2) sites. Disease stage at diagnosis was 
determined according to the International Staging System (ISS; I to III),
20
 Salmon and Durie 
stages I, II or III, and additionally according to renal function A or B.
21
 Performance status at 
ASCT was assessed with the Karnofsky score (≤ 80 indicating poor and > 80 good status).
22
 
Categorical variables were compared with the use of the Fisher’s exact test or the χ² test. 
Continuous variables were analyzed using the Kruskal-Wallis test for independent samples. 
Survival probabilities were estimated by the Kaplan–Meier method,
23 
and the Log-Rank test 
was used for univariate comparison. Median follow-up was calculated according to the 
reverse Kaplan-Meier method.
24 
Outcomes were artificially censored at three years. We used 
cumulative incidence analysis to assess NRM and labeled death from relapse as a competing 
event.
25,26
 The proportional hazards assumption was verified using graphical methods. 
Scaled Schoenfeld
27
 residuals and graphical checks proposed by Klein and Moeschberger
28
 
were performed to find evidence of violations. To minimize the effect of selection bias, we 
used a landmark analysis at six months whenever single and tandem ASCT were compared. 
To assess the multivariate effect of factors on each end point, we used the Cox proportional 
hazards model to estimate hazard ratios (HR).
29
 Only complete cases were included in the 
analysis. All tests were two-sided, with the type I error rate fixed at α = 0.05. All analyses 
were performed using the statistical software R, version 3.1.0 (R Foundation for Statistical 
Computing, Vienna, Austria) and SPSS Statistics 23 (SPSS, IBM Corp, Armonk, NY). 
Results 
Incidence and sites 
Among the total of 3744 patients identified in the registry, 14.5% (n = 543) had paraskeletal 
involvement (PS group) and 3.7% (n = 139) extramedullary organ involvement (EM group) 
while 81.8% (n = 3062) had no EMD (MM group). Between 2005 and 2014, the EMD 
incidence per year increased from 6.5% to 23.7%. 
Within the EM group, the involved sites were: kidney (27.3%, n = 38), skin (23.0%, n =32), 
lymph nodes (17.3%, n = 24), central nervous system (CNS; 10.1%, n = 14), lung and 
respiratory tract (6.5%, n = 9), gastrointestinal tract (GI) and liver (5.8%, n = 8), pleura and 
heart (5.0%, n = 7), and spleen, ovaries and testes (5.0%, n = 7). Most patients with EMD 
(93.5%, n = 639) presented with one involved site (PS1 and EM1), 5.7% (n = 36) had two 
sites, 0.7% (n = 5) had three sites while four and five sites were present in 0.1% (n = 1) of 
patients, respectively. Notably, within the PS group, all 19 patients with multiple (≥ 2) sites 
had only additional paraskeletal involvement (PS2) while further involvement in all 24 EM 
patients was also restricted to other organs (EM2).  
Patient and disease characteristics 
The median age at diagnosis was 59.8 years in both MM and PS, and 59.0 years in EM 
patients (p = 0.59). Among all groups were more males (57.9%) than females (42.1%). More 
EM patients (34.1%) had worse renal function (stage B) in comparison to PS (16.8%) and MM 
patients (17.3%; p < 0.001). Patients with EM involvement (28.3%) were more likely to have 
light chain disease compared to PS (22.5%) and MM patients (22.1%; p = 0.002). Detailed 
patients’ characteristics are listed in Table 1.  
Transplantation characteristics and responses 
The source of stem cells for all patients was peripheral blood. Upfront single ASCT was 
applied to 3391 and tandem ASCT to 353 patients. Time to first ASCT did not differ between 
the groups (p = 0.81). Complete remission (CR) before the first ASCT was reported in 21.5% 
PS, 11.7% EM and 19.1% MM patients while partial remission (PR) was achieved by 72.6% 
PS, 79.6% EM and 74.7% MM patients (p = 0.10; Table 1). After ASCT, complete response 
was achieved by 41.6% PS, 36.1% EM and 43.9% MM patients while 54.0% PS, 51.9% EM and 
49.8% MM patients showed partial response (p = 0.001). 
EMD and survival 
The median follow-up was 36.3 months (range, 1 to 118.9 months) after date of ASCT. In the 
univariate analysis, the MM and PS groups showed similar 3-year PFS of 47.9% (95% CI, 45.8 
to 50.1) vs. 50.0% (95% CI, 44.6 to 55.3; p = 0.78) and similar 3-year OS of 80.1% (95% CI, 
78.4 to 81.8) vs. 77.7% (95% CI, 73.3 to 82.1; p = 0.09; Figure 1A and B). In contrast, EM 
patients had a significantly worse 3-year PFS of 39.9% (95% CI, 30.3 to 49.5) in comparison to 
MM (p = 0.001) and PS patients (p = 0.007), and a significantly worse 3-year OS of 58.0% 
(95% CI, 48.1 to 67.9) compared to MM and PS patients (p < 0.001, respectively). Within the 
EM group, 3-year PFS differed according to involved organs: kidney (59.5%), skin (20.1%), 
lymph nodes (37.6%), CNS (47.9%), lung/respiratory tract (44.4%), GI/liver (22.5%), and 
spleen, ovaries and testes (60.0%; Table 2). 
Comparing the MM group without EMD to those with EMD, one involved site resulted in a 
similar 3-year PFS of 49.4% (95% CI, 44.6 to 54.3; p = 0.36) while multiple involved sites 
showed a worse PFS of 22.7% (95% CI, 5.2 to 40.2; p = 0.001; Figure 2A). Both one and 
multiple involved sites showed worse 3-year OS rates of 73.5% (95% CI, 69.2 to 77.7; p < 
0.001) and 71.4% (95% CI, 55.1 to 87.7; p = 0.05) in comparison to patients without EMD 
(80.1%; Figure 2B). 
By stratifying EMD groups according to one vs. multiple involved sites (PS1 vs. PS2, and EM1 
vs. EM2), PS patients showed no significant difference in 3-year PFS of 50.5% (95% CI, 45.0 to 
55.9%) vs. 36.0% (95% CI, 5.2 to 66.8%; p = 0.71), and OS of 77.2% (95% CI, 72.7 to 81.7%) vs. 
91.7% (95% CI, 76.0 to 100; p = 0.27). In EM patients, this comparison resulted in a 
significantly worse 3-year PFS of multiple sites in the univariate analysis: 44.7% (95% CI, 34.1 
to 55.3) vs. 13.9% (95% CI, 0 to 35.5%; p = 0.03; Figure 3A). In contrast, 3-year OS was 58.7% 
(95% CI, 47.9 to 69.5%) for EM1 vs. 57.5% (95% CI, 34.2 to 80.8%; p = 0.51; Figure 3B). 
Tandem transplantation and survival  
A landmark analysis was used to compare tandem and single ASCT, considering a total of 
3139 patients who were alive at six months. In patients without EMD, the comparison of 
tandem vs. single ASCT resulted in similar 3-year PFS: 53.8% (95% CI, 46.7 to 60.9) vs. 51.3% 
(95% CI, 48.9 to 53.7; p = 0.37), and similar 3-year OS: 84.7% (95% CI, 79.6 to 89.8) vs. 81.6% 
(95% CI, 79.8 to 83.4; p = 0.26). 
Patients with EMD showed a 3-year PFS of 59.0% (95% CI, 46.3 to 71.8) after tandem vs. 
53.0% (95% CI, 47.5 to 58.6) after single ASCT (p = 0.43) while 3-year OS was 77.0% (95% CI, 
66.1 to 87.9) vs. 76.9% (95% CI, 72.4 to 81.4; p = 0.91).  
Within each EMD group, PS patients showed a similar 3-year PFS of 59.4% (95% CI, 45.3 to 
73.6) after tandem vs. 54.3% (95% CI, 48.0 to 60.5; p = 0.44) after single ASCT and similar 3-
year OS of 82.6% (95% CI, 72.3 to 92.8) vs. 80.3% (95% CI, 75.6 to 85.1; p = 0.88). Patients 
with EM involvement showed no significant difference in both 3-year PFS and OS after 
tandem vs. single transplantation: 56.2% (95% CI, 27.2 to 85.3) vs. 48.3% (95% CI, 36.6 to 
60.1; p = 0.98), and 52.0% (95% CI, 20.0 to 84.0) vs. 64.9% (95% CI, 54.2 to 75.7; p = 0.39).  
Role of other factors on survival and causes of death 
All patients in CR before first ASCT showed a significantly better 3-year PFS of 59.8% (95% CI, 
55.3 to 64.3) compared to 30.7% (95% CI, 28.2 to 33.2) in PR and 24.7% (95% CI, 17.6 to 
31.8; p < 0.001) in less than PR. Three-year OS also significantly differed, with patients in CR 
showing 83.6% (95% CI, 80.2 to 87.0) compared to 78.8% (95% CI, 76.9 to 80.6) in patients 
with PR and 27.8% (95% CI, 20.8 to 34.9) in patients with less than PR (p < 0.001). 
Other factors that were associated with worse PFS in patients with EMD were: older age (p = 
0.04), transplantation before 2011 (p = 0.01), higher disease stage according to ISS (p = 0.01) 
and Salmon and Durie (p = 0.02), and lower remission status at transplantation (p < 0.001).  
Factors associated with worse OS in EMD patients were: transplantation before 2011 (p = 
0.02), higher disease stage according to ISS (p = 0.002) and Salmon and Durie (p = 0.02), and 
lower remission status at transplantation (p < 0.001). 
Non-relapse mortality at three years occurred in 3.0% (95% CI, 2.0 to 4.0) of MM, 3.0% (95% 
CI, 2.0 to 5.0) of PS patients, and 7.0% (95% CI, 2.0 to 12.0) of EM patients (p = 0.05). Main 
causes of death were relapse or progression (86.3%), infection (7.1%), secondary malignancy 
or post-transplant lymphoproliferative disorder (3.6%), organ damage or failure (1.8%), 
toxicity (0.4%) and unknown in 83 patients.  
Multivariate analyses 
A multivariable model was constructed to examine the effect of EMD on 3-year PFS and OS 
after adjusting for possible prognostic factors. All factors and covariates including 
corresponding references are listed in Table 3. To avoid linearly dependent covariates, we 
merged the disease group and the new variable of the number of involved sites into a five-
level variable consisting of patients without EMD (MM group) and patients with EMD 
according to number of involved sites (PS1, PS2, EM1 and EM2). Cox proportional hazards 
regression considering independent factors for worse PFS yielded significant results for EM2 
with a HR of 3.40 (95% CI, 1.74 to 6.61; p < 0.001). Interestingly, EM1 showed no difference 
in PFS compared to MM with a HR of 1.03 (95% CI, 0.66 to 1.62; p = 0.88). The comparison of 
PS and MM concerning PFS revealed no difference for PS1 a HR of 1.02 (95% CI, 0.83 to 1.27; 
p = 0.86) and a less clearly HR of 2.46 (95% CI, 0.92 to 6.62; p = 0.07) for PS2.  
In the OS analysis, EM1 and EM2 were associated with worse outcome, showing HRs of 2.30 
(95% CI, 1.43 to 3.70; p = 0.001) and 3.64 (95% CI, 1.48 to 8.94; p = 0.01). Patients with one 
site of PS involvement did less clearly differ from patients without EMD, with a HR of 1.33 
(95% CI, 0.98 to 1.83; p = 0.07) while PS2 resulted in similar outcome with a HR of 0.74 (95% 
CI, 0.10 to 5.32; p = 0.77).  
Tandem ASCT showed similar results considering 3-year PFS and OS compared to single 
ASCT, with HRs of 0.83 (95% CI, 0.66 to 1.06; p = 0.13) and 0.74 (95% CI, 0.51 to 1.09; p = 
0.13). 
However, other factors did significantly contribute to an increased risk of worse outcome 
(Table 3). For PFS, these factors were: ISS stage II and III, PR and less than PR at ASCT. Overall 
survival was significantly influenced by stage II and III according to ISS, male sex, PR and less 
than PR at ASCT, and the presence of heavy and light chains. 
Discussion 
Extramedullary disease in patients with MM is considered as poor prognostic factor. This 
EBMT registry study including 682 EMD patients identified an increase per year of EMD 
incidence at diagnosis from 2005 to 2014. We demonstrated that first-line ASCT resulted in 
at least similar 3-year PFS in patients with single sites of EMD compared to patients without 
EMD. This did less clearly translate into worse 3-year OS in single PS involvement while single 
sites of EM were significantly associated with worse outcome, which became even worse if 
multiple sites of organs were involved. Concerning treatment options for EMD at diagnosis, 
we found both first-line tandem and single ASCT resulting in similar 3-year PFS and OS. 
The evidence on the role of EMD at diagnosis after first-line ASCT is still limited. A 
retrospective single center study
30
 of 27 patients concluded that ASCT might overcome 
onset poor prognosis compared to patients without EMD while extramedullary organ 
involvement was present in only four patients and could underestimate its impact on 
outcome.
5
 A prospective study
31
 of patients in relapse with either soft-tissue or bone related 
involvement at a single institution found that bone-related relapses were associated with 
better OS, but treatments before diagnosis of extramedullary relapse significantly differed 
between groups. However, since different types of involvement were reported, this variable 
was examined closely. 
In our study, especially EM involvement in 139 MM patients was associated with lower rate 
of CR prior and after ASCT, a higher frequency of stage III according to ISS, and worse renal 
function. Moreover, the impact of the number of involved sites on outcome in EMD at 
diagnosis has not been described so far. We found 20% of all EMD patients having multiple 
sites of involvement, which is in line with previous reports (16%).
13
 Notably, the location of 
further involvements was only paraskeletal in the PS group and also restricted to other 
organs in the EM group.
32  
 
The use of radiation therapy might contribute to the difference in PFS and OS of patients 
with single sites of EMD compared to patients without EMD, because it is considered 
effective by reducing progression in patients with solitary osseous and extraosseous 
involvements.
33,34
 Especially, because reports about the efficacy of novel agents in these 
cohorts at diagnosis are very limited. Some results propose an induction bortezomib-based 
regimen followed by high-dose melphalan/ASCT for patients with paraskeletal rather than 
extramedullary involvement.
14,35-37
 In a retrospective study
38
 investigating carfilzomib alone 
or in combination as salvage therapy in relapse, presence of extramedullary involvement 
resulted in shorter duration of response compared to absent EMD, suggesting limited 
treatment effect. Smaller reports on the possible impact of immunomodulatory drugs 
showed partial efficacy regarding response rates in EMD patients.
10,39,40
  
Retrospective studies highlighted an extremely poor prognosis for CNS involvement with a 
median OS of less than six months.
41,42
 However, in addition to systemic anti-MM therapy, 
CNS irradiation and the use of novel combination therapies have been shown to improve the 
duration of response.
42
 With regard to these analyses lacking transplantation settings, we 
investigated survival according to involved sites in EM patients, finding most of the patients 
having kidney, skin or lymph node involvement. After upfront ASCT, best outcomes were 
found in kidney and CNS involvement while skin and lymph node involvement showed worse 
outcome. Interestingly, our CNS cohort showed higher rates of OS compared to previous 
reports, which might be due to the selection of patients with CNS involvement at diagnosis 
while most reports evaluated patients at later phases of the disease.
41,42
 
A pooled analysis of prospective studies regarding transplantation strategies suggested the 
superiority of tandem ASCT in patients with poor prognostic features at diagnosis.
4,43
 Our 
landmark analyses of EMD patients who received either tandem or single ASCT as first-line 
therapy found no difference considering PFS and OS. However, this analysis was conducted 
with the use of retrospective data and is therefore subject to the attendant limitations. 
Regression modeling and landmark analyses were performed as a means of controlling for 
differences of the patients, but such adjustment cannot account for all discrepancies in 
clinical and diagnostic characteristics between groups. The increasing incidence of EMD 
might be caused by a more frequent use of whole-body MRI or PET-CT in recent years. 
However, although recent evidence promotes the use of more sensitive imaging 
techniques,
44
 data are not routinely documented nor are part of routine diagnostics yet and 
were thus not available in our study.
45,46
 A randomized trial is the only way to overcome 
these challenges and to assess the definite impact of EMD in newly diagnosed MM patients 
after ASCT.  
In conclusion, this EBMT study identified an increase of incidence per year of EMD in newly 
diagnosed MM patients from 2005 to 2014. We revealed that first-line ASCT in patients with 
single sites of EMD (PS or EM) resulted in at least similar 3-year PFS compared to patients 
without EMD. Nevertheless, single EM involvement was associated with worse 3-year OS, 
which became even worse when multiple sites of organs were involved.  
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  Patients without EMD Patients with EMD 
 
  
Characteristic MM group PS group EM group Total  P 
No. of patients (%) 3062 (81.8) 543 (14.5) 139 (3.7) 3744   
Sex - no. (%)           
Female 1279 (41.8) 240 (44.2) 57 (41.0) 1576 (42.1) 0.55 
Male 1783 (58.2) 303 (55.8) 82 (59.0) 2168 (57.9)   
Age at diagnosis in years           
Median 59.8 59.8 59.0   0.59 
Range 27.4 to 77-7 26.8 to 76.8 31.8 to 72.8     
ISS - no. (%) 
    
  
I 781 (36.9) 158 (38.6) 29 (30.5) 968 (36.9)   
II 759 (35.8) 148 (36.2) 29 (30.5) 936 (35.7) 0.11 
III 578 (27.3) 103 (25.2) 37 (38.9) 781 (27.4)   
Unknown 944   134 44 1122   
Renal function - no. (%)           
A 2188 (82.7) 410 (83.2) 85 (65.9) 2683 (82.1) < 0.001 
B 458 (17.3) 83 (16.8) 44 (34.1) 585 (17.9)   
Unknown 416 50 10 476   
Karnofsky score - no. (%)           
Good  1877 (67.3) 344 (67.7) 81 (62.8) 2302 (67.2)   
Poor  914 (32.7) 164 (32.3) 48 (37.2) 1126 (32.8) 0.55 
Unknown 271 35 10 316   
Status at ASCT - no. (%)  
    
  
CR 580 (19.1) 115 (21.5) 16 (11.7) 711 (19.2)   
PR 2262 (74.7) 389 (72.6)  109 (79.6) 2760 (74.6) 0.10 
< PR 187 (6.2) 32 (6.0) 12 (8.8) 231 (6.2)   
Unknown 33 7 2 42   
Type of myeloma - no. (%) 
    
  
Light chain only 672 (22.1) 122 (22.5) 39 (28.3) 833 (22.4)   
Non-secretory 74 (2.4) 29 (5.4) 3 (2.2) 106 (2.9) 0.002 
Heavy and light chain 2292 (75.4) 389 (72.0) 96 (69.6) 2777 (74.7)   
Unknown 24 3 1 28   
Ig-type - no. (%) 
    
  
G 1648 (70.8) 282 (72.1) 72 (73.5) 2002 (71.1)   
A 634 (27.2) 101 (25.8) 22 (22.4) 757 (26.9) 0.51 
D/E/M 45 (1.9) 8 (2.0) 4 (4.1) 57 (2.0)   
Unknown 735 152 41 928   
Light chain type - no. (%)           
Kappa 1853 (63.7) 327 (65.1) 73 (55.7) 2253 (63.6) 0.13 
Lambda 1054 (36.3) 175 (34.9) 58 (44.3) 1287 (36.4)   
Unknown 155 41 8 204   
Number of sites - no. (%) 
    
  
0 3062 (100) 
  
3062 (81.8)  <0.001 
1 
 
524 (96.5) 115 (82.7) 639 (17.1) 
 
≥ 2 
 
19 (3.5) 24 (17.3) 43 (1.1)   
Year of ASCT - no. (%)           
< 2009 518 (16.9) 82 (15.1) 25 (18.0) 625 (16.7) 0.001 
2009 to 11 1400 (45.7) 204 (37.6) 62 (44.6) 1666 (44.5) 
 > 2011 1144 (37.4) 257 (47.3) 52 (37.4) 1453 (38.8)   
Time to 1st ASCT in months      
Median 6.2 6.2 6.1  0.81 
Range 1.1 to 11.9 2.1 to 11.9 3.9 to 11.9   
Type of ASCT - no.  
    
  
Tandem 249 89 15 353 
 Single 2813 454 124 3391   
 
Table 1. Patients, disease and transplantation characteristics. 
Abbreviations: EMD, extramedullary disease; MM, patients without extramedullary disease; 
PS, paraskeletal involvement; EM, extramedullary organ involvement; No., number; ISS, 
International Staging System; ASCT, autologous stem cell transplantation; CR, complete 
remission; PR, partial remission 
 
 
 
 
 
Site 
No. of  
patients (%) 
No. of 
deaths 
3-year PFS  
in % (95% CI) 
3-year OS  
in % (95% CI) 
Kidney 38 (27.3) 7 59.5 (41.1 to 77.9) 75.3 (59.0 to 91.7) 
CNS 14 (10.1) 4 47.9 (18.3 to 77.4) 64.3 (35.5 to 93.1) 
Lung / respiratory tract 9 (6.5) 3 44.4 (7.4 to 81.5) 41.7 (0 to 85.1) 
GI tract / liver 8 (5.8) 3 22.5 (0 to 58.8) 58.3 (22.0 to 94.7) 
Pleura / heart 7 (5.0) 5 NE NE 
Spleen / ovaries / testes 7 (5.0) 2 60.0 (17.1 to 100) 60.0 (17.1 to 100) 
Skin 32 (23.0) 10 20.1 (3.4 to 36.7) 53.3 (30.5 to 76.0) 
Lymph nodes 24 (17.3) 10 37.6 (16.4 to 58.7) 48.2 (25.1 to 71.3) 
 
Table 2. Involved sites in EM group and survival after ASCT. 
Abbreviations: EM, extramedullary organ; PFS, progression-free survival; OS, overall survival; 
ASCT, autologous stem cell transplantation; No., number; CI, confidence interval; CNS, 
central nervous system; GI, gastrointestinal; NE, not estimable 
 
  
 
 
 
  3-year PFS 3-year OS   
Factors – reference Hazard ratio (95% CI) P Hazard ratio (95% CI) P 
Group – MM without EMD 
 
< 0.001 
 
< 0.001 
PS1 1.02 (0.82 to 1.27) 0.86 1.33 (0.98 to 1.83) 0.07 
PS2 2.46 (0.92 to 6.62) 0.07 0.74 (0.10 to 5.32) 0.77 
EM1 1.03 (0.66 to 1.62) 0.88 2.30 (1.43 to 3.70) 0.001 
EM2 3.40 (1.74 to 6.61) < 0.001 3.64 (1.48 to 8.94) 0.01 
Sex – male 
   
  
Female 0.86 (0.74 to 1.01) 0.06 0.71 (0.56 to 0.91) 0.01 
Age in years - > 60 0.22 
 
0.45 
< 50 0.81 (0.74 to 1.03) 0.08 1.04 (0.73 to 1.48) 0.85 
50 to 60 0.95 (0.80 to 1.11) 0.50 1.17 (0.91 to 1.50) 0.21 
ISS – I 
 
< 0.001 
 
< 0.001 
II 1.48 (1.23 to 1.77) < 0.001 1.75 (1.29 to 2.37) < 0.001 
III 1.81 (1.46 to 2.24) < 0.001 2.68 (1.92 to 3.74) < 0.001 
Renal function – A 
  
  
B 0.99 (0.79 to 1.24) 0.93 1.25 (0.92 to 1.69) 0.16 
Status at ASCT – CR < 0.001 
 
0.02 
PR 1.58 (1.26 to 1.97) < 0.001 1.48 (1.05 to 2.08) 0.03 
< PR 2.18 (1.54 to 3.10) < 0.001 2.08 (1.22 to 3.54) 0.01 
Type of myeloma - light chain 0.10 
 
0.09 
Non-secretory 0.77 (0.42 to 1.43) 0.41 1.70 (0.80 to 3.61) 0.17 
Heavy and light 1.19 (0.98 to 1.46) 0.08 1.38 (1.01 to 1.88) 0.04 
Year of ASCT - > 2011 0.21 
 
0.91 
< 2009 1.22 (0.97 to 1.53) 0.09 1.07 (0.75 to 1.53) 0.71 
2009 to 2011 1.05 (0.88 to 1.26) 0.61 1.00 (0.76 to 1.33) 0.98 
Type of ASCT - single 
  
  
Tandem 0.83 (0.66 to 1.06) 0.13 0.74 (0.51 to 1.09) 0.13 
 
Table 3. Multivariate analysis. 
Abbreviations: PFS, progression-free survival; OS, overall survival; CI, confidence interval; 
MM, patients without extramedullary disease; PS, patients with paraskeletal involvement 
arisen from bone lesions; PS1, patients with paraskeletal involvement having one involved 
site; PS2, patients with paraskeletal involvement and multiple involved sites; EM1, patients 
with extramedullary organ involvement having one involved site; EM2, patients with 
extramedullary organ involvement and multiple involved sites; ISS, International Staging 
System; CR, complete remission; PR, partial remission; ASCT, autologous stem cell 
transplantation. 
  
 
 
Figure legends 
Figure 1. Progression-free survival (A) and overall survival (B) with numbers at risk of 
myeloma patients following upfront autologous stem cell transplantation according to 
presence of involvement: no EMD (MM), paraskeletal (PS) and extramedullary organ 
involvement (EM). 
Figure 1A. Abbreviations: PFS, progression-free survival; MM, patients without EMD; PS, 
patients with paraskeletal involvement; EM, patients with extramedullary organ 
involvement; Tx, transplantation; N, number. 
Figure 1B. Abbreviations: OS, overall survival; MM, patients without EMD; PS, patients with 
paraskeletal involvement; EM, patients with extramedullary organ involvement; Tx, 
transplantation; N, number. 
 
Figure 2. Progression-free survival (A) and overall survival (B) with numbers at risk of 
myeloma patients following upfront autologous stem cell transplantation according to 
number of involvements: 0, 1 and ≥ 2. 
Figure 2A. Abbreviations: PFS, progression-free survival; Tx, transplantation; N, number. 
Figure 2B. Abbreviations: OS, overall survival; Tx, transplantation; N, number. 
 
Figure 3. Progression-free survival (A) and overall survival (B) with numbers at risk of 
myeloma patients with extramedullary organ involvement following upfront autologous 
stem cell transplantation according to number of involvements: 1 and ≥ 2. 
Figure 3A. Abbreviations: PFS, progression-free survival; EM, patients with extramedullary 
organ involvement; EM1, patients with one site of EM; EM≥2, patients with two or more 
sites of EM; Tx, transplantation; N, number. 
Figure 3B. Abbreviations: OS, overall survival; EM, patients with extramedullary organ 
involvement; EM1, patients with one site of EM; EM≥2, patients with two or more sites of 
EM; Tx, transplantation; N, number. 



